A High-Throughput Screen for Teratogens Using Human Pluripotent Stem Cells

Toxicological Sciences

Volumn 137, Issue 1, 2014, Pages 76-90

  Kameoka, Sei ^a   Babiarz, Joshua ^a   Kolaja, Kyle ^a   Chiao, Eric ^a  

^a Non Clinical Safety   (United States)

Author keywords

Developmental toxicity; High throughput screening; Pluripotent stem cell; SOX17; Teratogenicity; Thalidomide

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; 6 AMINONICOTINAMIDE; BROXURIDINE; CATECHIN; CYTARABINE; DACTINOMYCIN; DASATINIB; DIETHYLSTILBESTROL; DOXORUBICIN; ESOMEPRAZOLE; FLUOROURACIL; GEFITINIB; IBUPROFEN; IMATINIB; ISOTRETINOIN; KETANSERIN; LISURIDE; MIANSERIN; NICOTINIC ACID; SORAFENIB; STREPTOMYCIN; SUNITINIB; TEGASEROD; TERATOGENIC AGENT; THALIDOMIDE; TRANSCRIPTION FACTOR SOX17; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; ZIPRASIDONE; BIOLOGICAL MARKER; PROTEIN KINASE INHIBITOR; SOX17 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DEVELOPMENTAL TOXICITY; DRUG SAFETY; EMBRYONIC STEM CELL; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MICROSCOPY; PHYSICAL CHEMISTRY; PLURIPOTENT STEM CELL; PREDICTIVE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TERATOGENICITY; CELL DIFFERENTIATION; DRUG EFFECTS; FEASIBILITY STUDY; GENETICS; METABOLISM; PATHOLOGY; PROCEDURES; QUALITY CONTROL; REPRODUCIBILITY; STANDARD; STANDARDS; TIME; TOXICITY TESTING; VALIDATION STUDY;

BENCHMARKING; BIOMARKERS; CELL DIFFERENTIATION; CELLS, CULTURED; FEASIBILITY STUDIES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PLURIPOTENT STEM CELLS; PROTEIN KINASE INHIBITORS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOXF TRANSCRIPTION FACTORS; TERATOGENS; TIME FACTORS; TOXICITY TESTS;

EID: 84891314148     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft239     Document Type: Article

References (31)

1. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., and Peterson, J. R. (2011). Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039-1045.
2. Bailey, G. P., Wise, L. D., Buschmann, J., Hurtt, M., and Fisher, J. E. (2009). Pre- and postnatal developmental toxicity study design for pharmaceuticals. Birth Defects Res. B Dev. Reprod. Toxicol. 86, 437-445.
3. Basketter, D. A., Clewell, H., Kimber, I., Rossi, A., Blaauboer, B., Burrier, R., Daneshian, M., Eskes, C., Goldberg, A., Hasiwa, N., et al. (2012). A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing - t4 report*. ALTEX 29, 3-91.
4. Basma, H., Soto-Gutiérrez, A., Yannam, G. R., Liu, L., Ito, R., Yamamoto, T., Ellis, E., Carson, S. D., Sato, S., Chen, Y., et al. (2009). Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology 136, 990-999.
5. Borowiak, M., Maehr, R., Chen, S., Chen, A. E., Tang, W., Fox, J. L., Schreiber, S. L., and Melton, D. A. (2009). Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell 4, 348-358.
6. Buesen, R., Genschow, E., Slawik, B., Visan, A., Spielmann, H., Luch, A., and Seiler, A. (2009). Embryonic stem cell test remastered: Comparison between the validated EST and the new molecular FACS-EST for assessing developmental toxicity in vitro. Toxicol. Sci. 108, 389-400.
7. Fedorov, O., Huber, K., Eisenreich, A., Filippakopoulos, P., King, O., Bullock, A. N., Szklarczyk, D., Jensen, L. J., Fabbro, D., Trappe, J., et al. (2011). Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem. Biol. 18, 67-76.
8. Festag, M., Viertel, B., Steinberg, P., and Sehner, C. (2007). An in vitro embryotoxicity assay based on the disturbance of the differentiation of murine embryonic stem cells into endothelial cells. II. Testing of compounds. Toxicol. In Vitro 21, 1631-1640.
9. Hartung, T., and Rovida, C. (2009). Chemical regulators have overreached. Nature 460, 1080-1081.
10. Hewitt, M., Ellison, C. M., Enoch, S. J., Madden, J. C., and Cronin, M. T. (2010). Integrating (Q)SAR models, expert systems and read-across approaches for the prediction of developmental toxicity. Reprod. Toxicol. 30, 147-160.
11. Kleinstreuer, N. C., Smith, A. M., West, P. R., Conard, K. R., Fontaine, B. R., Weir-Hauptman, A. M., Palmer, J. A., Knudsen, T. B., Dix, D. J., Donley, E. L., et al. (2011). Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. Toxicol. Appl. Pharmacol. 257, 111-121.
12. Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008). Pancreatic endoderm derived from human embryonic stem cells generates glucose- responsive insulin-secreting cells in vivo. Nat. Biotechnol. 26, 443-452.
13. Krug, A. K., Kolde, R., Gaspar, J. A., Rempel, E., Balmer, N. V., Meganathan, K., Vojnits, K., Baquié, M., Waldmann, T., Ensenat-Waser, R., et al. (2013). Human embryonic stem cell-derived test systems for developmental neurotoxicity: A transcriptomics approach. Arch. Toxicol. 87, 123-143.
14. Lauder, J. M., Wilkie, M. B., Wu, C., and Singh, S. (2000). Expression of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors in the mouse embryo. Int. J. Dev. Neurosci. 18, 653-662.
15. Marx-Stoelting, P., Adriaens, E., Ahr, H. J., Bremer, S., Garthoff, B., Gelbke, H. P., Piersma, A., Pellizzer, C., Reuter, U., Rogiers, V., et al. (2009). A review of the implementation of the embryonic stem cell test (EST). The report and recommendations of an ECVAM/ReProTect Workshop. Altern. Lab. Anim. 37, 313-328.
16. Mayshar, Y., Yanuka, O., and Benvenisty, N. (2011). Teratogen screening using transcriptome profiling of differentiating human embryonic stem cells. J. Cell. Mol. Med. 15, 1393-1401.
17. McLean, A. B., D'Amour, K. A., Jones, K. L., Krishnamoorthy, M., Kulik, M. J., Reynolds, D. M., Sheppard, A. M., Liu, H., Xu, Y., Baetge, E. E., et al. (2007). Activin a efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed. Stem Cells 25, 29-38.
18. Meganathan, K., Jagtap, S., Wagh, V., Winkler, J., Gaspar, J. A., Hildebrand, D., Trusch, M., Lehmann, K., Hescheler, J., Schlüter, H., et al. (2012). Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells. PLoS One 7, e44228.
19. Melchert, M., and List, A. (2007). The thalidomide saga. Int. J. Biochem. Cell Biol. 39, 1489-1499.
20. Muraki, M., Ohkawara, B., Hosoya, T., Onogi, H., Koizumi, J., Koizumi, T., Sumi, K., Yomoda, J., Murray, M. V., Kimura, H., et al. (2004). Manipulation of alternative splicing by a newly developed inhibitor of Clks. J. Biol. Chem. 279, 24246-24254.
21. Murry, C. E., and Keller, G. (2008). Differentiation of embryonic stem cells to clinically relevant populations: Lessons from embryonic development. Cell 132, 661-680.
22. Panzica-Kelly, J. M., Brannen, K. C., Ma, Y., Zhang, C. X., Flint, O. P., Lehman- McKeeman, L. D., and Augustine-Rauch, K. A. (2013). Establishment of a molecular embryonic stem cell developmental toxicity assay. Toxicol. Sci. 131, 447-457.
23. Pennings, J. L., van Dartel, D. A., Robinson, J. F., Pronk, T. E., and Piersma, A. H. (2011). Gene set assembly for quantitative prediction of developmental toxicity in the embryonic stem cell test. Toxicology 284, 63-71.
24. Seiler, A. E., and Spielmann, H. (2011). The validated embryonic stem cell test to predict embryotoxicity in vitro. Nat. Protoc. 6, 961-978.
25. Shuey, D., and Kim, J. H. (2011). Overview: Developmental toxicology: New directions. Birth Defects Res. B Dev. Reprod. Toxicol. 92, 381-383.
26. Spielmann, H., Pohl, I., Doring, M., and Liebsch, M. (1997). The embryonic stem cell test (EST), an in vitro embryotoxicity test using two permanent mouse cell lines: 3T3 fibroblasts and embryonic stem cells. In Vitro Toxicol. 10, 119-127.
27. van Dartel, D. A., Pennings, J. L., de la Fonteyne, L. J., van Herwijnen, M. H., van Delft, J. H., van Schooten, F. J., and Piersma, A. H. (2010). Monitoring developmental toxicity in the embryonic stem cell test using differential gene expression of differentiation-related genes. Toxicol. Sci. 116, 130-139.
28. Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73.
29. Zhang, Y., Li, W., Laurent, T., and Ding, S. (2012). Small molecules, big roles - the chemical manipulation of stem cell fate and somatic cell reprogramming. J. Cell Sci. 125(Pt 23), 5609-5620.
30. Zhu, S., Wurdak, H., Wang, J., Lyssiotis, C. A., Peters, E. C., Cho, C. Y., Wu, X., and Schultz, P. G. (2009). A small molecule primes embryonic stem cells for differentiation. Cell Stem Cell 4, 416-426.
31. zur Nieden, N. I., Davis, L. A., and Rancourt, D. E. (2010). Comparing three novel endpoints for developmental osteotoxicity in the embryonic stem cell test. Toxicol. Appl. Pharmacol. 247, 91-97.